Результаты поиска

New Treatment Options in Advanced Stage Follicular Lymphoma.

Follicular lymphoma is one of the most common non-Hodgkin's lymphomas with an expected survival of more than 20 years for the majority of patients. This impressive outcome has been achieved with the introduction of immunochemotherapy, as first line treatment with remissions lasting over 8 years, followed by other treatment options at first or subsequent relapse. However, certain groups of patients still have a poor prognosis. In recent years the efficacy of chemotherapy regimens has been augmented by new compounds selectively targeting the cell surface, intracellular pathways, and/or the micro

Совпадение в полном тексте источника
… Radioimmunotherapy ( 90 yttrium-ibritumomab-tiuxetan) may also represent an effective therapeutic approach in elderly patients with comorbidities not appropriate for transplantation. 37 New targets and compounds Targeting the cell surface This group consists of monoclonal and bispecific antibodies …

Gut Microbiota Dysbiosis and Dietary Interventions in Non-Hodgkin B-Cell Lymphomas: Implications for Treatment Response.

Non-Hodgkin B-cell lymphomas are a heterogeneous group of lymphoid malignancies with variable biological behavior, clinical presentation and treatment response. While chemoimmunotherapy remains the cornerstone of their management, growing evidence implicates the gut microbiota as a critical modulator of both lymphomagenesis and therapeutic efficacy. Gut microbiota dysbiosis, characterized by reduced microbial diversity and pathogenic taxonomic shifts, has been observed also in newly diagnosed patients and not just after therapy. This microbial imbalance contributes to mucosal barrier disruptio

Совпадение в полном тексте источника
… Assessing the Clinical Effectiveness of Radioimmunotherapy with Combined Radionuclide/Monoclonal Antibody Conjugates in Cancer Treatment: Insights from Randomised Clinical Trials Cancers 2025 17 1413 10.3390/cancers17091413 40361339 PMC12071007 21. Rao U.K. Majhail N.S. Blunk B. Abernathy K. …

Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.

Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs therefore combine the immune therapy with targeted chemotherapy. Due to the distinct biomarkers associated with lymphocytes and plasma cells, ADCs have emerged as a promising treatment option for lymphoid malignancies and multiple myeloma. Several ADCs have been approved for clinical applications: brentuximab vedotin, inotuzumab ozogamicin, moxetumomab pasudotox, and polatuzumab vedotin. More

Совпадение в полном тексте источника
… Single-agent InO was administered to 81 patients with R/R B cell NHL, predominantly follicular lymphoma (FL), who failed rituximab, rituximab plus chemotherapy, or radioimmunotherapy in a phase II trial ( NCT00868608 ). The study reported a 67% ORR, a 31% CR, and a median PFS of 12.7 months. … Goy A Forero A Wagner-Johnston N Christopher Ehmann W Tsai M Hatake K Ananthakrishnan R Volkert A Vandendries E Ogura M A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy Br J …

Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology.

In recent years, synthetic biology has been widely applied to engineer and program cellular behaviors. Using this approach, bacteria can be designed to express immunotherapeutic agents, improve tumor targeting, and deliver therapeutic payloads directly to tumor sites. To further improve efficacy, strategies such as hypoxia-responsive promoters, bacterial swarming, and extracellular vesicles (EVs) have been investigated, along with the synergistic effects of combining bacterial therapy with other treatments (e.g., photodynamic therapy, chemotherapy, immune checkpoint inhibitors). This review su

Совпадение в полном тексте источника
… In seminal work, Hannan et al. demonstrated complete tumor regression in prostate cancer models using ADXS-31-142 (a Listeria -based vaccine) combined with RT. 107 Subsequently, Qi et al. pioneered radioimmunotherapy by immobilizing ¹³¹I-labeled anti-PD-L1 antibodies on bacterial cellulose, which amplified …

Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.

T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated antigens, thereby engaging with CD3 on the T cell receptor. This linkage between tumor cells and T cells actively triggers T cell activation and initiates targeted killing of the identified tumor cells. These antibodies have emerged as one of the most promising avenues within tumor immunotherapy. However, despite success in treating hematological malignancies, significant advancements in solid tumors have yet to be explored. In this review, we aim to address the critical challenges associated with T

Совпадение в полном тексте источника
… Notably, using anti-GD2 BsAbs in pretargeted radioimmunotherapy for neuroblastoma has showcased improved therapeutic effects in terms of tumor shrinkage, elimination of micrometastases, and prevention of relapse 156 , 157 , 158 . … A self-assembling and disassembling (SADA) bispecific antibody (BsAb) platform for curative two-step pretargeted radioimmunotherapy Clin Cancer Res 27 2021 532 541 32958698 10.1158/1078-0432.CCR-20-2150 PMC7855367 138 van de Donk N.W.C.J. O’Neill C. de Ruijter M.E.M. Verkleij C.P.M. Zweegman S. …

Первая стадия испытания иополосина I 131 и Dexametasone в пациентах с повторной релапсированной/отправленной миеломой.

Справочная информация/цели: Пациенты, страдающие рецидивом/отторжением множественных миелом (RRMM), имеют плохие результаты в плане выживания и ограниченные возможности лечения. Все более широкое использование многоагентной терапии для более ранних направлений лечения и новых классов лекарственных препаратов, включая целевые агенты BCMA в последующих направлениях терапии, обусловило необходимость в новаторских платформах лечения у пациентов, которые вновь вернулись к этим стандартным подходам к уходу или отстали от них. Иопофосин I 131 a 131iodid (131I)-фосфолипидный спаривание, использующее с

Совпадение в полном тексте источника
… Rationales, evidence and design considerations for fractionated radioimmunotherapy. Cancer. 2002;94:1332–1347. doi: 10.1002/cncr.10304. 22. Durie B.G.M., Harousseau J.-L., Miguel J.S., Blade J., Barlogie B., Anderson K., Gertz M., Dimopoulos M., Westin J., Sonneveld P., et al. …

Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach.

Metastases are the primary cause of death among cancer patients and efficacious new treatments are sorely needed. Targeted alpha-emitting radiopharmaceuticals that are highly cytotoxic may fulfill this critical need. The focus of this paper is to describe and explore a novel technology that may improve the therapeutic effect of targeted alpha therapy by combining two radionuclides from the same decay chain in the same solution. We hypothesize that the dual targeting solution containing bone-seeking 224Ra and cell-directed complexes of progeny 212Pb is a promising approach to treat metastatic c

Совпадение в полном тексте источника
… Meredith R Torgue J Shen S Fisher D Banaga E Bunch P Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med. ( 2014 ) 55 : 1636 – 42 . 10.2967/jnumed.114.143842 25157044 PMC4486012 …

Update on current pancreatic treatments: from molecular pathways to treatment.

Pancreatic cancer is still diagnosed at a late stage although we have novel diagnostic tools. Pancreatic cancer chemotherapy treatment resistance is observed and therefore novel treatments are in need. Anti-cancer stem cell therapy, combination of chemotherapy and/or radiotherapy with immunotherapy, proteins/enzymes and gene therapy are currently under evaluation. Targeted treatment with tyrosine kinase inhibitors is also administered and novel inhibitors are also under evaluation. In the current review we present recent data from our search within the year 2018.

Совпадение в полном тексте источника
… Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma Frontiers in immunology 2018 9 1955. doi:10.3389/fimmu.2018.01955 30214445 10.3389/fimmu.2018.01955 PMC6125378 18 Sugyo A Tsuji AB Sudo H Koizumi M Ukai Y Kurosawa G Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy …

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.

Skeletal involvement in metastatic castrate-resistant prostate cancer (mCRPC) is common and results in significant morbidity and mortality. The interaction of prostate cancer with the bone microenvironment contributes to progression of cancer in the bone leading to skeletal-related events (SREs). Studies aimed at targeting the bone have been carried out over the recent years. Bisphosphonates are synthetic pyrophosphate analogs first investigated for their role in SRE prevention with zoledronic acid as the main bisphosphonate that is approved by the US Food and Drug Administration for retardati

Совпадение в полном тексте источника
… Radioimmunotherapy with alphaemitting nuclides. Eur J Nucl Med. 1998 ; 25 ( 9 ): 1341 – 51 . 9724387 10.1007/s002590050306 57. Baidoo K.E. , Yong K. , Brechbiel M.W. Molecular pathways: targeted alpha-particle radiation therapy. …

Bispecific antibodies and nanotechnology: a strategic alliance in cancer immunotherapy.

Bispecific antibodies (bsAbs), designed to recognize two distinct antigens or epitopes, enable innovative mechanisms of action for emerging generations of cancer immunotherapies. Despite their potential, bsAb therapeutics face several challenges related to their biodistribution and pharmacokinetics, which often result in a suboptimal efficacy/toxicity balance. Starting with a brief description of the relevance of bsAbs in cancer immunotherapy, this review aims to critically analyze the synergistic potential of nanotechnology and bsAb technology oriented to enhance therapeutic efficiency while

Navigating through novelties concerning mCRC treatment-the role of immunotherapy, chemotherapy, and targeted therapy in mCRC.

Over the course of nearly six decades since the inception of initial trials involving 5-FU in the treatment of mCRC (metastatic colorectal cancer), our progressive comprehension of the pathophysiology, genetics, and surgical techniques related to mCRC has paved the way for the introduction of novel therapeutic modalities. These advancements not only have augmented the overall survival but have also positively impacted the quality of life (QoL) for affected individuals. Despite the remarkable progress made in the last two decades in the development of chemotherapy, immunotherapy, and target the

Совпадение в полном тексте источника
… With an ever-increasing understanding of genomic alterations among mCRC patients, there is a promising perspective in exploring novel approaches from recent advancements in genetics and immunology such as the development of therapies focused on changing the immunological phenotype of mCRC e.g., radioimmunotherapy …

A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023.

BackgroundBispecific antibody (BsAb)-based cancer immunotherapy has provided new avenues for the treatment of various malignancies. The approval of Blinatumomab has encouraged further investigation into these treatments, and a series of preclinical and clinical trials have been conducted, together with the publication of numerous articles. Here, the knowledge structure of BsAb-based cancer immunotherapy is summarized using bibliometric analysis to provide in-depth insight into current research trends and foci.MethodsThe studies included in the bibliometric analysis of BsAbs in cancer immunothe

Совпадение в полном тексте источника
… As shown in Fig. 8 B, keywords such as “EpCAM”, “Radioimmunotherapy”, and “pre-targeting” showed greater heat values in the early years of the field. …

Mapping the research trends and hotspots on solid pulmonary nodules from 2000-2024: insights from bibliometric analysis.

BackgroundDue to extensive low-dose computed tomography (CT) screening, the detection rate of solid pulmonary nodules (PNs) is constantly rising. However, existing studies lack a comprehensive understanding of its emerging research trends and interdisciplinary progress, especially in terms of artificial intelligence (AI) integration and molecular characteristics. In this study, we conduct a comprehensive bibliometric analysis to clarify the current research trends and predict future research hotspots in this field, in order to improve diagnostic accuracy, reduce overtreatment, and promote inno

Совпадение в полном тексте источника
… CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer. J Exp Clin Cancer Res 2024;43:89. 10.1186/s13046-024-03007-w 46. Chen S, Mo W, Jiang W, et al. …

Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy.

Non-small cell lung cancer (NSCLC) is a highly malignant tumor, with a significant mortality and morbidity. With the development of tumor immunotherapy, chimeric antigen receptor T cells (CART) gets increasingly attention and achieves prominent contributions in the treatment of hematologic malignancies. However, CART therapy for NSCLC proceeds slowly and further researches need to be investigated. In our study, we performed bioinformatics analysis to evaluate the significant role of CD147 in NSCLC. The expression level of CD147 was detected in human NSCLC cell lines and NSCLC tissues. Meanwhil

Совпадение в полном тексте источника
… Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials Int. J. Radiat. Oncol. Biol. Phys. 65 2 2006 435 444 16690431 10.1016/j.ijrobp.2005.12.034 26 Zhang Z. Zhang Y. Sun Q. Feng F. Huhe M. Mi L. Chen Z. …

Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment.

Primary gastric lymphoma (PGL) is the most common extranodal non-Hodgkin lymphoma and represents a wide spectrum of disease, ranging from indolent low-grade marginal zone lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma to aggressive diffuse large B-cell lymphoma. The PGL is a relatively rare cancer and easily misdiagnosed due to its unspecific symptoms of the digestive tract. The medical literature and ongoing clinical trials were reviewed on the clinical presentation, diagnosis, prognosis, prevention, and treatment of PGL. Primary gastric lymphoma is an event in the course of ca

Совпадение в полном тексте источника
… Identification of cell surface antigens has led to the introduction of monoclonal antibodies such as R and radioimmunotherapy, which have led to a more targeted approach with an important effect for the overall management of lymphoma. …

Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?

Patients with metastatic cancers often require radiotherapy (RT) as a palliative therapy for cancer pain. RT can, however, also induce systemic antitumor effects outside of the irradiated field (abscopal effects) in various cancer entities. The occurrence of the abscopal effect is associated with a specific immunological activation in response to RT-induced cell death, which is mainly seen under concomitant immune checkpoint blockade. Even if the number of reported apscopal effects has increased since the introduction of immune checkpoint inhibition, its occurrence is still considered rare and

Совпадение в полном тексте источника
… Clinical Studies on Abscopal Effect Even after almost a decade of radioimmunotherapy and numerous studies on different immunotherapeutic agents, the occurrence of abscopal immune reactions has not been regularly achieved in clinical trials. …

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Therapeutic antibodies have revolutionized hematology, offering targeted and effective treatments for both malignant and non-malignant diseases. In hematologic malignancies, anti-CD20, anti-CD19, anti-CD38, and anti-B-cell maturation antigen (BCMA) antibodies have markedly improved survival outcomes, whereas antibody-drug conjugates and bispecific antibodies continue to expand therapeutic possibilities. Besides cancer, complement inhibitors such as eculizumab, ravulizumab, and the recently approved crovalimab have redefined paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic synd

Совпадение в полном тексте источника
… Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 2002;20:2453–2463. doi: 10.1200/JCO.2002.11.076. 4. …

Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers.

Recently, targeted nanoparticles (NPs) have attracted much attention in cancer treatment due to their high potential as carriers for drug delivery. In this article, we present a novel bioconjugate (DOX-AuNPs-Tmab) consisting of gold nanoparticles (AuNPs, 30 nm) attached to chemotherapeutic agent doxorubicin (DOX) and a monoclonal antibody, trastuzumab (Tmab), which exhibited specific binding to HER2 receptors. The size and shape of synthesized AuNPs, as well as their surface modification, were analyzed by the TEM (transmission electron microscopy) and DLS (dynamic light scattering) methods. Bi

Совпадение в полном тексте источника
… Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy. Nanomaterials. 2020;10:2067. doi: 10.3390/nano10102067. 21. …

Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma.

Bendamustine (Treanda, Ribomustin) was recently approved by the US Food and Drug Administration (FDA) for treatment of patients with rituximab refractory indolent lymphoma and is expected to turn into a frontline therapy option for indolent lymphoma. This compound with amphoteric properties was designed in the former Germany Democratic Republic in 1960s and re-discovered in 1990s with multiple successive well-designed studies. Bendamustine possesses a unique mechanism of action with potential antimetabolite properties, and only partial cross-resistance with other alkylators. Used in combinatio

Совпадение в полном тексте источника
… Treatment with ibritumomabtiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–9. doi: 10.1200/JCO.2002.11.017. 16. Ozegowski W, Krebs D. …

Influence of Fibroblasts on Mammary Gland Development, Breast Cancer Microenvironment Remodeling, and Cancer Cell Dissemination.

The stromal microenvironment regulates mammary gland development and tumorigenesis. In normal mammary glands, the stromal microenvironment encompasses the ducts and contains fibroblasts, the main regulators of branching morphogenesis. Understanding the way fibroblast signaling pathways regulate mammary gland development may offer insights into the mechanisms of breast cancer (BC) biology. In fact, the unregulated mammary fibroblast signaling pathways, associated with alterations in extracellular matrix (ECM) remodeling and branching morphogenesis, drive breast cancer microenvironment (BCM) rem

Совпадение в полном тексте источника
… Furthermore, targeting Sdc-1 with radioimmunotherapy has proved to be a successful therapeutic strategy for the treatment of mice with TNBC [ 255 ]. FN, highly expressed by BCAFs, represents another promising target for cancer therapy. …